GGrantIndex
← Leaderboards

Stuart J Wong

Medical College Of Wisconsin

$1,964,401
Attributed
$7,334,812
Total exposure
5
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY201725
$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,334,812 · 5

By mechanism

UG1$4,389,281 · 1
R01$2,569,015 · 1
R21$375,000 · 1
M01$1,516 · 2

Top collaborators

Most similar at Medical College Of Wisconsin

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchClinical TrialsPre-ClinicalMissionFundingMentorsLeadershipInvestmentsCancer CenterCancer Clinical TrialEastern Cooperative Oncology GroupDisciplineFacultyMedical SchoolsCancer TherapyAdultGrowthInfrastructureClinical Trials NetworkAmerican College Of Radiology Imaging NetworkLeadCancer DiagnosisConduct Clinical TrialsMalignant Neoplasms

Grant awards (19)

MCW NCTN Lead Academic Participating Site Administrative Supplement$569,544
UG1 · FY2025 · CA · contact PI
MCW NCTN Lead Academic Participating Site$609,494
UG1 · FY2024 · CA · contact PI
MCW NCTN Lead Academic Participating Site$596,655
UG1 · FY2023 · CA · contact PI
MCW NCTN Lead Academic Participating Site$595,016
UG1 · FY2022 · CA · contact PI
Inhibition of Oral Tumorigenesis by Antitumor B$471,422
R01 · FY2022 · CA
MCW NCTN Lead Academic Participating Site$824,283
UG1 · FY2021 · CA · contact PI
Inhibition of Oral Tumorigenesis by Antitumor B$403,481
R01 · FY2021 · CA
MCW NCTN Lead Academic Participating Site$595,016
UG1 · FY2020 · CA · contact PI
Inhibition of Oral Tumorigenesis by Antitumor B$183,047
R01 · FY2020 · CA
MCW NCTN Lead Academic Participating Site$599,273
UG1 · FY2019 · CA · contact PI
Inhibition of Oral Tumorigenesis by Antitumor B$481,383
R01 · FY2019 · CA
Inhibition of Oral Tumorigenesis by Antitumor B$504,001
R01 · FY2018 · CA
Inhibition of Oral Tumorigenesis by Antitumor B$525,681
R01 · FY2017 · CA
Molecular Characterization of p53R2 in Head and Neck Ca$187,500
R21 · FY2004 · CA
A Phase I/II Trial of Pre-Operative Capecitabine Radiation for Rectal Cancer$758
M01 · FY2004 · RR
Radiosensitization in Advanced Squamous Cell Carcinoma$758
M01 · FY2004 · RR
Molecular Characterization of p53R2 in Cancer$187,500
R21 · FY2003 · CA
RADIOSENSITIZATION IN SQUAMOUS CELL CARCINOMA OF HEAD/NECK$0
M01 · FY2000 · RR
RADIOSENSITIZATION IN SQUAMOUS CELL CARCINOMA OF HEAD/NECK$0
M01 · FY2000 · RR